1. Home
  2. JHI vs IXHL Comparison

JHI vs IXHL Comparison

Compare JHI & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo John Hancock Investors Trust

JHI

John Hancock Investors Trust

N/A

Current Price

$12.90

Market Cap

119.3M

Sector

Finance

ML Signal

N/A

Logo Incannex Healthcare Inc.

IXHL

Incannex Healthcare Inc.

N/A

Current Price

$2.86

Market Cap

97.6M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
JHI
IXHL
Founded
N/A
2001
Country
United States
Australia
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
119.3M
97.6M
IPO Year
1994
2024

Fundamental Metrics

Financial Performance
Metric
JHI
IXHL
Price
$12.90
$2.86
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
19.5K
3.3M
Earning Date
01-01-0001
02-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$12,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.61
$0.11
52 Week High
$14.51
$6.39

Technical Indicators

Market Signals
Indicator
JHI
IXHL
Relative Strength Index (RSI) 28.80 51.32
Support Level N/A $0.32
Resistance Level $14.01 $5.17
Average True Range (ATR) 0.17 0.44
MACD -0.06 -0.22
Stochastic Oscillator 10.82 0.62

Price Performance

Historical Comparison
JHI
IXHL

About JHI John Hancock Investors Trust

John Hancock Investors Trust is a United States-based diversified, closed-end management investment company. It seeks to generate income for distribution to its shareholders. The secondary objective of the company is capital appreciation. The portfolio composition of the fund comprises corporate bonds, U.S. government agencies, preferred securities, asset-backed securities, common stocks, short-term investments, and others. The company's portfolio includes Corporate Bonds, Term Loans, U.S Government Agency, and Others.

About IXHL Incannex Healthcare Inc.

Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.

Share on Social Networks: